Hyperlipidemia Market Report 2026

Hyperlipidemia Market Overview

• Hyperlipidemia market size has reached to $20.92 billion in 2025 • Expected to grow to $25.54 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Elevating Demand In The Hyperlipidemia Market Driven By Rising Incidences Of Heart Disease • Market Trend: Revolutionary Advances in Hyperlipidemia Treatment for Pediatric Patients • North America was the largest region in 2025.

What Is Covered Under Hyperlipidemia Market?

Hyperlipidemia is a medical condition characterized by abnormally high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It is a common metabolic disorder and a significant risk factor for cardiovascular diseases. The main types of hyperlipidemias are familial, acquired. Familial hyperlipidemia refers to a genetic disorder characterized by inherited high levels of lipids, such as cholesterol and triglycerides, in the bloodstream, significantly increasing the risk of cardiovascular diseases. The various treatment includes statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination and others. The various route of administration includes oral and parenteral. These are used by various end-users such as hospitals, specialty clinics, home care and others.

What Is The Hyperlipidemia Market Growth Forecast?

The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $25.54 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing adoption of PCSK9 inhibitors, growth in familial hyperlipidemia diagnosis, expansion of personalized lipid therapies, rising demand for preventive cardiology, improving access to advanced treatments. Major trends in the forecast period include increasing adoption of combination lipid-lowering therapies, rising focus on early screening and preventive care, growing use of injectable biologics for high-risk patients, expansion of home-based and long-term lipid management, stronger emphasis on lifestyle-integrated treatment approaches.

Global Hyperlipidemia Market Segmentation

1) By Type: Familial Hyperlipidemia, Acquired Hyperlipidemia 2) By Treatment: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Other Treatments 3) By Route of Administration: Oral, Parenteral 4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegments: 1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH), Familial Combined Hyperlipidemia, Familial Dysbetalipoproteinemia 2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia, Secondary Hyperlipidemia, Drug-Induced Hyperlipidemia

What Is The Driver Of The Hyperlipidemia Market?

Increasing incidences of chronic disorders such as heart disease are expected to propel the growth of the hyperlipidemia market going forward. Heart diseases refer to diseases that affect the heart and its functioning. Hyperlipidemia treatment helps people suffering from heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function and reducing the need for invasive interventions. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, increasing incidences of chronic disorders such as heart disease drive the growth of the hyperlipidemia industry.

Key Players In The Global Hyperlipidemia Market

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co. Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd.

Global Hyperlipidemia Market Trends and Insights

Major companies operating in the hyperlipidemia market are focused on developing innovative products, such as advanced low-density lipoprotein cholesterol-lowering therapies, to sustain their position in the market. For example, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced the U.S. Food & Drug Administration (FDA) approval of Praluent (alirocumab) Injection. It represents a significant advancement in treating heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, offering a targeted approach to manage dangerously high low-density lipoprotein cholesterol (LDL-C) levels. Recent FDA approval is supported by Phase 3 trial results showing a 31% reduction in LDL-C levels with regular dosing. Its well-established safety profile, consistent with adults, reassures families and healthcare providers, while its status as the first therapy targeting the genetically-validated PCSK9 protein marks a milestone in heart disease treatment. Together, these features position Praluent as a crucial option for managing high cholesterol in children with HeFH.

What Are Latest Mergers And Acquisitions In The Hyperlipidemia Market?

In June 2025, Eli Lilly and Company, a US-based biopharmaceutical company, acquired Verve Therapeutics for up to $1.3 billion. With this acquisition, Lilly aims to leapfrog chronic cholesterol management by integrating Verve’s in vivo gene-editing platform to deliver a potential one-time therapy for hyperlipidemia. Verve Therapeutics is a US-based clinical-stage company developing base-editing medicines (e.g., VERVE-102 targeting PCSK9) to durably lower LDL-cholesterol and other lipoprotein drivers of atherosclerotic cardiovascular disease.

Regional Outlook

North America was the largest region in the hyperlipidemia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hyperlipidemia Market?

The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hyperlipidemia Market Report 2026?

The hyperlipidemia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hyperlipidemia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.